Mirvetuximab Soravtansine Active Not Recruiting Phase 3 Trials for Malignant Peritoneal Neoplasm / Fallopian Tubes Cancer / Epithelial Ovarian Cancer Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04296890A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression